Pioneering a New Era in Immunotherapy

At Voltron Therapeutics, we are dedicated to advancing the science of immunotherapy through our revolutionary therapeutic platform.

Designed to precisely target tumors and pathogens, our platform unlocks powerful, balanced immune responses while reducing development costs, risks, and timelines.

Voltron’s technology platform trains, utilizes and more fully engages multiple components of the immune system to identity, target and kill a specific disease. The platform drives an immune response that can attack, for example, a cancer target in multiple ways. The technology has the capability to deliver a wide variety of therapies/mechanisms for more effective treatments to improve patient outcomes.

Voltron was founded in 2017 to lead and accelerate cutting-edge discoveries at Massachusetts General Hospital and Harvard’s Vaccine and Immunotherapy Center. Voltron’s technology combines world-class research with real-world clinical ambition. Our goal is to deliver novel, highly efficacious treatments for patients facing cancers and infectious diseases.

Voltron holds an exclusive worldwide license to this technology.

Technology Platform

 

Precisely target tumors and pathogens, unlocking a powerful and balanced immune response that is designed to improve patient outcomes

  • Superior Immune Activation: Platform outperforms traditional adjuvants like Alum in potency and immune engagement.

  • Unmatched Flexibility: Our platform enables rapid customization and scalability against unique tumor targets and pathogens.

  • Rapid Development: Stockpiled fixed components paired with variable payloads accelerate clinical readiness.

  • Excellent Safety Profile: Therapeutic and vaccine candidates have shown excellent tolerability in preclinical models, with no dose-limiting toxicities observed.

  • Strong Intellectual Property: Expanding patent portfolio protects and enhances Voltron’s competitive edge.

At Voltron Therapeutics, we are reshaping the future of immunotherapy for a broad range of cancers and infectious diseases. We believe in smarter science, faster solutions, and better outcomes for patients worldwide.

Join us in building a stronger immune future.

Patrick Gallagher, CEO